麻豆传媒

Four children with traditionally incurable brain cancers are still alive years after receiving an experimental immune-boosting cell therapy in a clinical trial. Three of them even display no evidence of disease.

鈥淭hese children are getting to grow up 鈥� it鈥檚 truly awesome,鈥� says at Children鈥檚 National Hospital in Washington DC.

The experimental treatment, called tumour-associated antigen (TAA) T-cell therapy, was given to 33 children and young adults with either newly diagnosed diffuse intrinsic pontine glioma (DIPG), a highly aggressive form of brain cancer, or other brain tumours that hadn鈥檛 responded to standard treatments. The trial focused on these tumour types because 鈥渢hey鈥檙e universally fatal, there鈥檚 nothing else for them鈥�, says team member , also at Children鈥檚 National Hospital.

Children with DIPG typically survive for less than a year, but one of the treated children with this condition is still alive more than two years after receiving the TAA T-cell therapy.

Among the participants with other kinds of brain tumours, three responded remarkably well to the therapy. They had aggressive forms of recurrent glioblastoma, astroblastoma or medulloblastoma and had previously gone through up to 17 rounds of treatments like chemotherapy and radiation that had been unsuccessful. Since receiving the TAA T-cell therapy, the three children are alive with no evidence of disease between two and five years on.

鈥淚鈥檓 still in contact with one of the families and they鈥檙e unbelievably grateful that their child is still with them today,鈥� says Bollard.

Free newsletter

Sign up to Health Check

Sign up to newsletter

The trial was small and didn鈥檛 include a control group to compare the therapy with standard treatment, but Bollard says 鈥渨e鈥檙e very excited because, although it was only a phase-I safety study, there did seem to be a signal of efficacy鈥�. It is still unclear why the treatment worked for some children but not others, she says.

鈥淣o one is jumping up and down and saying 鈥榯his is it鈥� just yet, but it is encouraging and it鈥檚 one step further along in our understanding of how to use cellular therapies to attack brain tumours,鈥� says at Queensland Children鈥檚 Hospital in Australia.

The therapy involves taking a sample of a person鈥檚 blood, collecting immune cells called T-cells and essentially training them in a lab to target three protein markers, known as antigens, that are commonly found in paediatric brain tumours, says Bollard. This is done by exposing the T-cells to other cells that present these antigens, then selectively multiplying the T-cells that recognise them. The multiplied T-cells are then returned to the person intravenously, so their own immune system becomes better at fighting their cancer.

TAA T-cell therapy is different to CAR T-cell therapy, which is now widely used to treat blood cancers, but generally lacks efficacy against solid tumours. In CAR T-cell therapy, people鈥檚 T-cells are genetically engineered to give them synthetic receptors called chimeric antigen receptors, which help them detect single antigens on cancer cells, usually those in blood. In contrast, TAA T-cell therapy involves no genetic engineering, allows targeting of multiple cancer antigens and may work more broadly for solid tumours.

Pancreatic cancer halted by virus injection in three patients

A cancer-killing virus has stopped pancreatic tumours from growing and spreading in three people in an initial safety trial, raising hopes that it may help to beat the deadly condition

So far, TAA T-cell therapy seems to have fewer side effects than CAR T-cell therapy, perhaps because it doesn鈥檛 genetically modify a person鈥檚 T-cells, says Bollard. In the trial, most patients tolerated the therapy well, with fatigue and headache being the most common side effects. Two people experienced tumour swelling, but this may have been because they already had large tumour volumes, says Bollard.

The team is now beginning two more clinical trials of the therapy for children with brain tumours. In one, the TAA T-cell therapy will be combined with an ultrasound technique that opens the blood-brain barrier to hopefully allow more of the T- cells to get into the brain. In the other trial, each patient鈥檚 tumour will be genetically sequenced to identify its unique antigens, allowing their T-cells to be specifically trained to target these antigens in a personalised way.

鈥淔or the last 20 or so years, we haven鈥檛 really moved the dial in terms of improving survivability for these paediatric brain tumours, so it鈥檚 exciting to have a whole different treatment area opening up,鈥� says Hassall.